Free Trial

FNY Investment Advisers LLC Has $463,000 Stock Position in Amedisys, Inc. (NASDAQ:AMED)

Amedisys logo with Medical background

FNY Investment Advisers LLC increased its stake in Amedisys, Inc. (NASDAQ:AMED - Free Report) by 6,942.3% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,000 shares of the health services provider's stock after buying an additional 4,929 shares during the quarter. FNY Investment Advisers LLC's holdings in Amedisys were worth $463,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of AMED. Norges Bank acquired a new stake in Amedisys during the 4th quarter valued at approximately $83,061,000. Wealthfront Advisers LLC acquired a new stake in Amedisys during the 4th quarter valued at approximately $72,970,000. Pentwater Capital Management LP grew its stake in Amedisys by 178.3% during the 4th quarter. Pentwater Capital Management LP now owns 1,180,000 shares of the health services provider's stock valued at $107,132,000 after purchasing an additional 756,000 shares in the last quarter. AQR Arbitrage LLC grew its stake in Amedisys by 59.1% during the 4th quarter. AQR Arbitrage LLC now owns 471,965 shares of the health services provider's stock valued at $42,812,000 after purchasing an additional 175,311 shares in the last quarter. Finally, Birnam Oak Advisors LP acquired a new stake in Amedisys during the 4th quarter valued at approximately $15,832,000. Institutional investors and hedge funds own 94.36% of the company's stock.

Amedisys Stock Performance

NASDAQ:AMED traded up $0.38 during trading hours on Thursday, reaching $97.89. 410,518 shares of the stock were exchanged, compared to its average volume of 418,159. The stock has a market capitalization of $3.21 billion, a P/E ratio of 36.12, a P/E/G ratio of 1.32 and a beta of 0.94. Amedisys, Inc. has a 52 week low of $82.15 and a 52 week high of $98.95. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 0.27. The firm has a 50 day simple moving average of $94.41 and a 200-day simple moving average of $92.05.

Amedisys (NASDAQ:AMED - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.12. The business had revenue of $594.78 million for the quarter, compared to the consensus estimate of $597.43 million. Amedisys had a return on equity of 12.52% and a net margin of 3.79%. The business's revenue was up 4.1% on a year-over-year basis. During the same quarter last year, the business posted $1.03 EPS. As a group, sell-side analysts forecast that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

AMED has been the subject of a number of recent analyst reports. Stephens restated an "equal weight" rating and set a $101.00 price objective on shares of Amedisys in a research note on Tuesday, March 4th. Wall Street Zen downgraded Amedisys from a "strong-buy" rating to a "buy" rating in a report on Saturday, May 24th. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and set a $100.00 target price on shares of Amedisys in a report on Wednesday, April 16th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $100.75.

Get Our Latest Analysis on Amedisys

Amedisys Profile

(Free Report)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Featured Stories

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Should You Invest $1,000 in Amedisys Right Now?

Before you consider Amedisys, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.

While Amedisys currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Hot Growth Stocks to Watch Right Now!
Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines